The traditional antiseizure medication (ASM) market is highly genericized, and there are limited branded ASMs left without generic equivalents. Additionally, though a wide variety of drugs have been approved, there are still unmet needs in this market to be addressed, including refractory epilepsy and rare epileptic syndromes. The breadth of each drug’s label is highly pertinent to its competitive edge and provides impetus for the ongoing uptake of branded antiepileptics. Even in the saturated focal onset seizure (FOS) market, broadening usage to the monotherapy context and including pediatric patients are likely to bolster uptake. Further expansion to other seizure types, specific subpopulations such as refractory epilepsy patients, or rare epilepsy syndromes can also help to maximize commercial potential.